



U.S. ARMY PUBLIC HEALTH CENTER

8252 Blackhawk Road, Aberdeen Proving Ground, Maryland 21010-5403

Toxicology Study No. S.0002728b-15, March 2018
Protocol No. 0FMA-92-iv16-06-01A,B,C,D,E
Toxicology Directorate

Microtox Toxicity Testing of the Novel Energetics, 1,4-dinitroglycoluril (DNGU), 3,4-dinitropyrazole (DNP), 1,4,7-trinitrohexahydro-1H-imidazo[4,5-b]pyrazine-2(3H)-one (HK-56), 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105), and 2,4,6-trinitro-3-bromoanisole (TNBA)

Prepared by: Dr. Emily N. Reinke, Health Effects Division

Approved for public release; distribution unlimited.

Toxicity Study: 500c

ACKNOWLEDGEMENTS

I would like to acknowledge the support and encouragement provided to this effort by Dr. Robin Nissan of the Department of Defense Strategic Environmental Research and Development Program. I also acknowledge Dr. William Eck for his critical review and comments on this report.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.
PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 09/04/2018	2. REPORT TYPE Technical Report	3. DATES COVERED (From - To) February 2017-April 2018
--	---	---

4. TITLE AND SUBTITLE Microtox Toxicity Testing of the Novel Energetics, 1,4-Dinitroglycoluril (DNGU), 3,4-Dinitropyrazole (DNP), 1,4,7-trinitrohexahydro-1Himidazo[4,5-b]pyrazine-2(3H)-one (HK-56), 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105), and 2,4,6-trinitro-3-bromoanisole (TNBA)	5a. CONTRACT NUMBER
	5b. GRANT NUMBER
	5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S) Emily N. Reinke, Ph.D., D.A.B.T Alyssa Sikorski, M.S.	5d. PROJECT NUMBER
	5e. TASK NUMBER
	5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Army Public Health Center, Toxicology Directorate 5158 Black Hawk Road, Aberdeen Proving Ground, MD 21010-5403	8. PERFORMING ORGANIZATION REPORT NUMBER S.0002728b-15
---	--

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Strategic Environmental Research and Development Program (SERDP) 4800 Mark Center Drive Suite 17D03 Alexandria, VA 22350-3605	10. SPONSOR/MONITOR'S ACRONYM(S) SERDP
	11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION/AVAILABILITY STATEMENT
UNLIMITED

13. SUPPLEMENTARY NOTES

14. ABSTRACT
The energetic and toxicological properties of 1,4-dinitroglycoluril (DNGU), 3,4-dinitropyrazole (DNP), 1,4,7-trinitrohexahydro-1H-imidazo[4,5-b]pyrazine-2(3H)-one (HK-56), 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105), and 2,4,6-trinitro-3-bromoanisole (TNBA) were determined in support of their evaluation as potential replacements for energetics in current use, such as hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) and trinitrotoluene (TNT). This study evaluated the aquatic toxicity of DNGU, DNP, HK-56, LLM-105, and TNBA with the Microtox® Acute Toxicity Test System.

15. SUBJECT TERMS
1,4-dinitroglycoluril, DNGU, 3,4-dinitropyrazole, DNP, 1,4,7-trinitrohexahydro-1H-imidazo[4,5-b]pyrazine-2(3H)-one, HK-56, 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide, LLM-105, 2,4,6-trinitro-3-bromoanisole, TNBA in vitro, microtox, aquatic toxicity

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON	
a. REPORT	b. ABSTRACT	c. THIS PAGE			Emily N. Reinke	
U	U	U	SAR	33	19b. TELEPHONE NUMBER (Include area code) 410-436-2896	

INSTRUCTIONS FOR COMPLETING SF 298

1. REPORT DATE. Full publication date, including day, month, if available. Must cite at least the year and be Year 2000 compliant, e.g. 30-06-1998; xx-06-1998; xx-xx-1998.

2. REPORT TYPE. State the type of report, such as final, technical, interim, memorandum, master's thesis, progress, quarterly, research, special, group study, etc.

3. DATE COVERED. Indicate the time during which the work was performed and the report was written, e.g., Jun 1997 - Jun 1998; 1-10 Jun 1996; May - Nov 1998; Nov 1998.

4. TITLE. Enter title and subtitle with volume number and part number, if applicable. On classified documents, enter the title classification in parentheses.

5a. CONTRACT NUMBER. Enter all contract numbers as they appear in the report, e.g. F33315-86-C-5169.

5b. GRANT NUMBER. Enter all grant numbers as they appear in the report. e.g. AFOSR-82-1234.

5c. PROGRAM ELEMENT NUMBER. Enter all program element numbers as they appear in the report, e.g. 61101A.

5e. TASK NUMBER. Enter all task numbers as they appear in the report, e.g. 05; RF0330201; T4112.

5f. WORK UNIT NUMBER. Enter all work unit numbers as they appear in the report, e.g. 001; AFAPL30480105.

6. AUTHOR(S). Enter name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. The form of entry is the last name, first name, middle initial, and additional qualifiers separated by commas, e.g. Smith, Richard, J, Jr.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES). Self-explanatory.

8. PERFORMING ORGANIZATION REPORT NUMBER. Enter all unique alphanumeric report numbers assigned by the performing organization, e.g. BRL-1234; AFWL-TR-85-4017-Vol-21-PT-2.

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES). Enter the name and address of the organization(s) financially responsible for and monitoring the work.

10. SPONSOR/MONITOR'S ACRONYM(S). Enter, if available, e.g. BRL, ARDEC, NADC.

11. SPONSOR/MONITOR'S REPORT NUMBER(S). Enter report number as assigned by the sponsoring/monitoring agency, if available, e.g. BRL-TR-829; -215.

12. DISTRIBUTION/AVAILABILITY STATEMENT. Use agency-mandated availability statements to indicate the public availability or distribution limitations of the report. If additional limitations/ restrictions or special markings are indicated, follow agency authorization procedures, e.g. RD/FRD, PROPIN, ITAR, etc. Include copyright information.

13. SUPPLEMENTARY NOTES. Enter information not included elsewhere such as: prepared in cooperation with; translation of; report supersedes; old edition number, etc.

14. ABSTRACT. A brief (approximately 200 words) factual summary of the most significant information.

15. SUBJECT TERMS. Key words or phrases identifying major concepts in the report.

16. SECURITY CLASSIFICATION. Enter security classification in accordance with security classification regulations, e.g. U, C, S, etc. If this form contains classified information, stamp classification level on the top and bottom of this page.

17. LIMITATION OF ABSTRACT. This block must be completed to assign a distribution limitation to the abstract. Enter UU (Unclassified Unlimited) or SAR (Same as Report). An entry in this block is necessary if the abstract is to be limited.

Sponsor

Strategic Environmental Research and Development Program (SERDP)
4800 Mark Center Drive
Suite 17D03
Alexandria, VA 22350-3605

Study Title

Toxicology Study No. S.0002728b-15
Protocol No. 0FMA-92-iv16-06-01A,B,C,D,E

Microtox Toxicity Testing of the Novel Energetics, 1,4-Dinitroglycoluril (DNGU), 3,4-Dinitropyrazole (DNP), 1,4,7-trinitrohexahydro-1Himidazo[4,5-b]pyrazine-2(3H)-one (HK-56), 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105), and 2,4,6-trinitro-3-bromoanisole (TNBA)

Authors

Alyssa Sikorski, M.S.
Emily N. Reinke, Ph.D., D.A.B.T.

Study Completed

April 2018

Performing Laboratory

U.S. Army Public Health Center
Toxicology Directorate
Health Effects Division
MCHB-PH-HEF
Aberdeen Proving Ground, MD 21010-5403

Laboratory Project ID


Protocol No. 0FMA-92-iv16-06-01A, B, C, D, E

Good Laboratory Practice Compliance Statement

The study described in this report was conducted in compliance with Title 40, Code of Federal Regulations (CFR), Part 792, Good Laboratory Practice Standards, except for the following:

1. The test article characterization (purity) was conducted by the manufacturer and it is not known whether the testing was done in compliance with the above regulation.
2. Due to time constraints, the method of analysis for these compounds could not be validated by the Laboratory Sciences Directorate (LS) prior to the study start in compliance with study protocol and modification requirements. Because of this the dosing solutions used for all strains were verified after being frozen (at - 80 degrees C) until the method could be validated by the LAB after the study was completed.
3. Due to calibration error, the balance used for verifying pipette function was flagged as "in need of repair." Four years of weight set verification data logs were reviewed and the balance is operable and functioning properly. The balance was continued in use and weight set verification was performed prior to each day's use.

No deviations from the aforementioned regulation affected the quality or integrity of the study or the interpretation of the results.



Emily N. Reinke, Ph.D., D.A.B.T.
Study Director
Health Effects Division

18 April 2018
Date

Toxicology Study No. S.0002728b-15, April 2018

Table of Contents

	<u>Page</u>
1 Summary	1
1.1 Overview	1
1.2 Purpose	1
1.3 Conclusions	2
1.4 Recommendations	2
2 References	2
3 Authority	2
4 Background	3
5 Materials	5
5.1 Test Substance	5
5.2 Test System	5
5.3 Positive Control	6
5.4 Quality Assurance	6
6 Methods	6
6.1 Experimental Design	6
6.2 Range Finding	6
6.3 Cytotoxicity Test	7
6.4 Data analysis	8
7 Results and Discussion	8
7.1 Microtox Toxicity and Risk Assessment	8
7.2 Criteria for a Valid Assay	10
8 Conclusions	10
9 Recommendations	10
10 Point of Contact	11

Appendices		<u>Page</u>
A	References.....	A-1
B	Quality Assurance Statement	B-1
C	Archives and Study Personnel.....	C-1
D	Microtox Test Reagents.....	D-1
E	DNGU Microtox Test Raw Data and Calculations.....	E-1
F	DNP Microtox Test Data Tables and Calculations	F-1
G	HK-56 Microtox Test Data Tables and Calculations.....	G-1
H	LLM-105 Microtox Test Data Tables and Calculations.....	H-1
I	TNBA Microtox Test Data Tables and Calculations	I-1

Figure	
1	Molecular Structure of the Compounds5

Tables	
1	Critical Events4
2	Microtox Toxicity and Risk Assessment.....7
3	Ecotoxicity Assessment Scale8

Toxicology Study No. S.0002728b-15
Protocol No. 0FMA-92-iv16-06-01A, B, C, D, E
Microtox Toxicity Testing of the Novel Energetics, 1,4-Dinitroglycoluril (DNGU),
3,4-Dinitropyrazole (DNP), 1,4,7-trinitrohexahydro-1Himidazo[4,5-b]pyrazine-
2(3H)-one (HK-56), 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105),
and 2,4,6-trinitro-3-bromoanisole (TNBA)

1 Summary

1.1 Overview

The energetic and toxicological properties of 1,4-dinitroglycoluril (DNGU), 3,4-dinitropyrazole (DNP), 1,4,7-trinitrohexahydro-1H-imidazo[4,5-b]pyrazine-2(3H)-one (HK-56), 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105), and 2,4,6-trinitro-3-bromoanisole (TNBA) were determined in support of their evaluation as potential replacements for energetics in current use, such as hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) and trinitrotoluene (TNT). This study evaluated the aquatic toxicity of DNGU, DNP, HK-56, LLM-105, and TNBA with the Microtox[®] Acute Toxicity Test System. Data from this study is used to assist in making environment and health-based decisions regarding the design and selection of formulas and materials for further development of new munition compounds.

1.2 Purpose

The purpose of this study is to provide environmental and occupational health information on new or replacement energetic compounds for military use. This information is critical to the research, development, testing, and evaluation (RDT&E) of munition formulation alternatives. This study addresses, in part, the environmental safety and occupational health (ESOH) requirements outlined in Department of the Army (DA) Regulation 200-1 [1]; DA Regulation 40-5 [2]; and DA Regulation 70-1 [3]; Department of Defense Instruction (DoDI) 4715.4 [4]; and Army Environmental Research and Technology Assessment requirement PP-3-02-05 [5], Compliant Ordnance Lifecycle for Readiness of the Transformation and Objective Forces. This program is under the direction of the Department of Defense Strategic Environmental Research and Development Program (SERDP).

Research, development, testing, training, and use of substances potentially less hazardous to human health and the environment is vital to the readiness of the U.S. military. Safeguarding the health of Soldiers, Civilians, and the environment requires an assessment of alternatives before they are fielded. Continuous assessments begun early in the RDT&E process can save significant time and effort during RDT&E, as well as over the life cycle of the items developed. Residues of pyrotechnics, propellants, explosives, and incendiaries have been found in soil, air, surface, and groundwater samples, creating environmental problems and interfering with training activities.

Toxicology Study No. S.0002728b-15, April 2018

The Department of Defense is identifying replacements for substances causing environmental and/or occupational risks to health. The purpose of this toxicology study was to examine the aquatic toxicity of DNGU, DNP, HK-56, LLM-105, and TNBA using the Microtox Acute Toxicity Assay, and to conduct the assay consistent with Good Laboratory Practice (GLP) Standards.

1.3 Conclusions

This study reports the aquatic toxicity for the new munitions compounds DNGU, DNP, HK-56, LLM-105 and TNBA via the Microtox Acute Toxicity assay. According to U.S. Environmental Protection Agency (EPA) Hazard Categories, results show that DNGU was not considered toxic, with a maximal concentration of 1,000 milligrams per liter (mg/L), DNP was slightly toxic (EC_{50} : 13.55 mg/L); HK-56 is considered moderately toxic with an EC_{50} of 1.1 mg/L. LLM-105 and TNBA are highly toxic (0.8 and 0.4 mg/L respectively). LLM-105, HK-56, and TNBA would be considered hazards for aquatic life, while DNP and DNGU are not by Organization for Economic Co-operation and Development (OECD) hazard class guidelines [6].

1.4 Recommendations

The acute aquatic toxicity of LLM-105, HK-56, and TNBA is of concern and further testing and evaluation should be continued to determine if environmental releases are likely following use of these test articles. The limited toxicity of DNGU and DNP is encouraging; however, exposure to DNP can potentially cause skin sensitizing reactions [7, 8], so further analysis of exposure scenarios is recommended. The water solubility of both of these compounds (3 grams per liter (g/L) and 51.93 g/L) may be of concern; however, the lower toxicity may mitigate the issue. LLM-105 and TNBA were also found to potentially act as skin sensitizers based upon additional skin sensitization testing carried out by U.S. Army Public Health Center (APHC) [9]. This raises additional concerns based on their high toxicity and relatively high water solubility. Further *in vitro* and *in vivo* testing is warranted for any of these compounds if development is to continue.

2 References

See Appendix A for list of references.

3 Authority

Military Interdepartmental Purchase Request No. W74RDV5291790. This technical report addresses, in part, the environment, safety and occupational health (ESOH) requirements outlined in DoDI 4715.4 [4], Department of the Army Regulation (AR) 200-1, Environmental Protection and Enhancement[1]; AR 40-5, Preventive Medicine [2]; and AR 70-1, Army Acquisition Policy [3]; DoDI 4715.4, Pollution Prevention [4]; and Army Environmental Research and Technology Assessment Requirement PP-3-02-05, Compliant Ordnance Lifecycle for Readiness of the Transformation and Objective Forces . Strategic Environmental Research and Development Program conducted it as part of an on-going effort.

4 Background

Current regulations require the assessment of human health and environmental effects arising from exposure to substances in soil, surface water, and ground water. Applied after an item has been fielded, these assessments can reveal the existence of adverse environmental and human health effects that must be addressed, often at substantial cost. It is more efficient to begin the assessment of exposure, effects, and environmental transport of military-related compounds/substances early in the RDT&E process to avoid unnecessary costs, conserve physical resources, and sustain the health of those potentially exposed. A goal of this program is to investigate these new compounds with operational and/or environment, safety, and occupational health issues. The candidates under development for high-density energetics include DNGU, DNP, HK-56, LLM-105, and TNBA.

National defense requires the development of unique energetic compounds to perform specialized mission requirements. These requirements also include the sustainable use of these materials in the environment, particularly during training operations. In the past, the use of RDX (1,3,5-hexahydro-1,3,5-trinitrotriazine) and other energetics have been a concern due to their ability to contaminate groundwater and thus enter into the drinking water supply. Unexploded ordnance and low-order detonations have become sources of ground water contamination and have affected drinking water resources.

The Centers for Disease Control and Prevention (CDC), Agency for Toxic Substances and Disease Registry (ATSDR) has developed an acute oral minimum risk level (MRL) for RDX of 60 micrograms per kilograms per day ($\mu\text{g}/\text{kg}\text{-day}$) based on its epileptiform seizure neurotoxicity in humans and rodents [10-13]. The EPA has derived a chronic reference dose (RfD) of 3 $\mu\text{g}/\text{kg}\text{-day}$ based prostatic inflammation in rodents. RDX is also classified as a possible carcinogen [14, 15].

TNT is acutely toxic to rats causing ataxia, tremors, and mild convulsions; oral LD_{50} values range from 660 to 1,320 mg/kg. The RfD for subchronic and chronic oral exposures of 0.0005 mg/kg-day is based on a LOAEL of 0.5 mg/kg-day for liver effects in dogs. TNT is classified in weight-of-evidence Group C, possible human carcinogen [16, 17]. TNT has caused anemia in the workforce at ammunition manufacturing facilities.

The DoD SERDP is dedicated to finding replacements for RDX and TNT that will reduce or eliminate the health risks from environmental and occupational exposure and will reduce adverse ESOH effects; RDX adversely affects the readiness and costs associated with training [18]. To support the development of sustainable, low toxicity materials for use, fast, high-throughput methods are needed to assess relative toxicity of new munition compounds as they are developed. Toxicity tests can be conducted *in vivo* and *in vitro*. *In vitro* methods have the advantage of being relatively inexpensive, high-throughput, and capable of addressing many mechanistic issues at the cellular and molecular level, while reducing or eliminating animal use for testing. Specifically for the newly developed materials, the *in vitro* tests are most suitable and effective screening tools, given that often very limited amounts of test substances are available. By identifying ESOH effects early in the acquisition process, unacceptable replacement compounds can be identified. The energetic and toxicological properties of DNGU,

Toxicology Study No. S.0002728b-15, April 2018

DNP, HK-56, LLM-105, and TNBA are being evaluated as potential replacements for TNT and RDX.

The Toxicology Directorate (TOX) of the APHC has been tasked with providing aquatic acute toxicity data for DNGU, DNP, HK-56, LLM-105, and TNBA to determine their potential to negatively affect the environment. The data from these studies will help in making recommendations for continued development and toxicity testing resulting in appropriate exposure guidance.

Microtox is a toxicity testing system that uses a strain of naturally occurring luminescent bacteria, *Aliivibrio fischeri* (formerly *Vibrio fischeri* and still referred to as *V. fischeri* by the supplier of the reagents, Modern Water, and will be referred to as *V. fischeri* in this report). The marine bacterial bioluminescence is tied directly to cellular respiration which is fundamental to cellular metabolism and associated life processes. These non-pathogenic, marine, luminescent bacteria are sensitive to a broad range of toxicants resulting in a decreased rate of respiration and a corresponding decrease in the rate of luminescence. Reduction of the microorganism's light emission is proportional to the toxicity expressed as EC50 (the midpoint of the effective concentration). The Microtox test has been shown to be an effective screening tool in assessing toxicity of varied chemical compounds comparing with other bioassays. The Microtox Acute Toxicity Test has been validated by the industrial, academic, and governmental testing communities and achieved official "Standards Status" in several countries including the following:

- International Organization for Standards (ISO) 11348-3 (United States of America)
- Standard Method 8050 (United States of America)
- Association Française de Normalisation (AFNOR) T90-320 (France)
- German Institute for Standardization (DIN) 38412 (Germany)

This assay is useful in predicting/screening for adverse effects to aquatic organisms.

This report describes the mutagenic effect of DNGU, DNP, HK-56, LLM-105, and TNBA in the Microtox acute toxicity assay. Table 1 identifies the critical events and dates of this study.

Table 1. Critical Events

Critical Event	Date of Event
Non-Animal Use Protocol Approved	29 June 2016
Study Start Date	13 February 2017
Experimental Start Date	10 April 2017
Experimental Completion Date	23 June 2017
Study Completion Date	9 April 2018

5 Materials

5.1 Test Substance

Synthesis of DNGU (Chemical Abstracts Service Registry Number (CASRN) 55510-04-08), DNP (CASRN 38858-92-3), HK-56 (CASRN unknown), LLM-105 (CASRN 194486-77-6), and TNBA (CASRN unknown) was completed by Holston Army Ammunition Plant, Kingsport, Tennessee. Purity analyses for these compounds were not available. Figure 1 shows the molecular structures of the compounds.

DNGU was soluble at 100 mg/mL, HK-56 and DNP were soluble at 50 mg/mL, LLM-105 was soluble at 10 mg/mL and TNBA was soluble at 1 mg/mL. Initial solubility was determined by solubility checks in the Ames assay [19, 20]. At the end of study, the final serial dilutions were frozen and later analyzed by the APHC Method Development Section Client Services Division (PHC-MDV-CSD) for dose validation. The method of analysis was validated prior to dosing solution verification by the PHC-MDV-LCD; the validation data is kept by MDV and is available for review. The contributing scientist analytical report from PHC-MDV-LCD is archived with the study records.






				
1,4-Dinitroglycoluril (DNGU)	3,4-Dinitropyrazole (DNP)	1,4,7-Trinitrohexahydro-1H-imidazo[4,5-b]pyrazin-2(3H)-one (HK-56)	2,6-Diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105)	2,4,6-Trinitro-3-bromoanisole (TNBA)

Figure 1. Molecular Structure of the Compounds

5.2 Test System

The Microtox Acute Toxicity Test reagent and associated media and solutions were obtained from Modern Water, Inc., New Castle, DE. The reagent is a freeze-dried preparation of a specially selected strain of the marine bacterium *V. fischeri* (also known as *A. fischeri*, formerly known as *Photobacterium phosphoreum*, NRRL number B-11177). A list of media, solutions and other necessary test materials with expiration dates and lot numbers is provided in Appendix D. All reagents were stored according to manufacturer instructions as described in the Toxicology Standing Operating Procedure (SOP) 037 and study protocol [21, 22].

Toxicology Study No. S.0002728b-15, April 2018

5.3 Positive Control

Phenol is the recommended standard or positive control for the test system. The phenol standard was purchased from Sigma-Aldrich (St. Louis, MO). Each vial of lyophilized *V. fischeri* was tested against the standard following reconstitution. Only vials with a calculated EC₅₀ of 13-26 mg/L at 5 min were qualified for further use.

5.4 Quality Assurance

APHC policy requires that all experiments and studies conducted by any element of the APHC TOX will be compliant with the GLP Standards [23]. For this study, the test article dictates that the following GLP standard applies [24]

Code of Federal Regulations (CFR), Title 40: Protection of Environment, Part 792-Good Laboratory Practice Standards.

According to this policy and that, these results may be used in regulatory decisions involving the EPA, these Microtox tests were conducted in compliance with GLP standards and followed the appropriate regulatory testing guidelines.

In compliance with the GLP requirements, the PHC Quality Systems and Regulatory Compliance Office (QSARC) audited critical phases of this study. A Quality Assurance Statement is provided in Appendix B, which provides the dates of these audits along with the audited phases and the dates that the results of the audits were reported to Management and the Study Director. The additional Quality Assurance/GLP requirement of archives location is provided in Appendix C as well as the names of personnel contributing to the performance of this study.

6 Methods

6.1 Experimental Design

The experimental design and general procedures of this study were conducted under the APHC TOX SOP 037 for the Microtox Acute Toxicity Assay [21]. The test kit is designed to determine the aquatic toxicity of a test material in compliance with the APHC TOX Type Protocol: "*Microtox Toxicity Testing System*" [22], and modifications. The modifications to the protocol are approved and signed by the Study Director and QSARC. The electronic and hard copy versions of the protocol modifications are saved and archived with the protocol and the raw data.

6.2 Range Finding

DNGU, DNP, HK-56, LLM-105, and TNBA were dissolved in DMSO at their solubility limit. The solubility of each test article was determined previously in the Ames test [20]. Samples were serially diluted 1:2 in DMSO and further diluted 1:100 in diluent. Eight concentrations were tested for the range finding. Reconstituted *V. fischeri* was added to each test concentration (10 µL) and samples were incubated and tested for luminescence at 5, 15, and 30 minutes using the Microtox Model 500 Analyzer (Modern Water, Inc.). The EC₅₀ from the range finding

Toxicology Study No. S.0002728b-15, April 2018

determined the final test concentration range (See Appendix E-I for final chemical specific ranges).

6.3 Cytotoxicity Test

Following the range finding, each test article was tested in duplicate on three separate days. On each testing day, test articles were prepared in DMSO at 100x the top dose as determined in the range finding and serially diluted 1:2 in DMSO to create an 8 dose testing range. Samples were diluted 1:100 into 1 mL diluent and 10 μ L reconstituted *V. fischeri* was added to each sample and luminescence measured at 5, 15, and 30 minutes as above. At the end of the study, the samples were analyzed by the PHC-MDV-LCD. The final dilution of the empirical starting stock solution for DNGU would theoretically be, for example, 781.2 μ g/mL.

- The validated concentrations of the final serial dilution for DNGU were:
 - Test 1 – 834 μ g/mL
 - Test 2 – 870 μ g/mL
 - Test 3 – 852 μ g/mL

- The validated concentrations of the final serial dilution for DNP were:
 - Test 1 – 34.1 μ g/mL
 - Test 2 – 22.2 μ g/mL
 - Test 3 – 40.0 μ g/mL

- The validated concentrations of the final serial dilution for HK-56 were:
 - Test 1 – 3.3 μ g/mL
 - Test 2 – 3.9 μ g/mL
 - Test 3 – 3.6 μ g/mL

- The validated concentrations of the final serial dilution for LLM-105 were:
 - Test 1 – 4.9 μ g/mL
 - Test 2 – 1.8 μ g/mL
 - Test 3 – 6.1 μ g/mL
 - Test 4 – 9.6 μ g/mL

- The validated concentrations of the final serial dilution for TNBA were:
 - Test 1 – 2.1 μ g/mL
 - Test 2 – 2.7 μ g/mL
 - Test 3 – 2.7 μ g/mL

The concentrations of the initial concentrates were back-calculated from these verified concentrations.

6.4 Data Analysis

Raw luminescence data were recorded at 5, 15, and 30 minutes by the Microtox analyzer. The EC₅₀ values at 5, 15, and 30 minutes were given by the MicrotoxOmni software and further fitted to the Hill function using GraphPad PRISM 4[®]. All data (prints and files) were archived.

7 Results and Discussion

7.1 Microtox Toxicity and Risk Assessment

Toxicity of DNGU, DNP, HK-56, LLM-105, and TNBA to marine bacteria, *V. fischeri*, was measured by the Microtox acute toxicity test system at 5, 15, and 30 minutes. For each test compound, three individual experiments were performed in duplicate. Table 2 presents the toxicity data (EC₅₀ and the 95 percent Confidence Interval) and risk assessment. Best-fit EC₅₀ values for 5, 15, and 30 minutes were calculated in GraphPad Prism version 5.04 using percent effect data calculated by MicrotoxOmni. The tables and figures within Appendices E–I presents data that was further analyzed by performing the Hill function using GraphPad Prism version 5.04. The X and Y axis represent log concentrations of the test article and the percentage of the effect bacteria of the control, respectively.

Comparisons of toxicity results using these methods for a variety of compounds found that *V. fischeri* were, in most cases, more sensitive than other aquatic organisms [25-27]. Thus, the results with Microtox tests are often useful screens in the assessment of relative toxicity to aquatic organisms. We used the aquatic toxicity criteria of the EPA, the OECD and the Global Harmonization System (GHS) to categorize the potential ecotoxicity of these new compounds (Table 3) [6, 28, 29]. This evaluation suggests LLM-105 and TNBA are “Highly Toxic” and potentially very toxic to aquatic life; HK-56 is “Moderately Toxic” and potentially toxic to aquatic life; DNP is “Slightly Toxic” and potentially harmful to aquatic life; and DNGU is “Practically Nontoxic” (Table 2).

Toxicology Study No. S.0002728b-15, April 2018

Table 2. Microtox Toxicity and Risk Assessment

Compound	Microtox EC ₅₀ (mg/L) [95 percent CI]			Hazard Categories (USEPA 2017)	Hazard Classes (OECD 2001)	Acute Aquatic Toxicity (GHS 2005)
	5 min	15 min*	30 min			
DNGU	492.3 [451.0-537.4]	273.7 [251.7-297.6]	173.9 [158.1-191.4]	Practically Nontoxic	—	—
DNP	13.6 [12.6-14.8]	10.9 [10.2-11.8]	9.1 [8.3-10.1]	Slightly Toxic	Acute Toxicity III (harmful to aquatic life)	Acute Cat. III
HK-56	2.6 [2.2-3.0]	1.1 [0.9-1.2]	0.6 [0.5-0.7]	Moderately Toxic	Acute Toxicity II (toxic to aquatic life)	Acute Cat. II
LLM-105	1.1 [1.0-1.2]	0.8 [0.7-0.9]	0.7 [0.6-0.8]	Highly Toxic	Acute Toxicity I (very toxic to aquatic life)	Acute Cat. I
TNBA	0.8 [0.4-1.4]	0.4 [0.3-0.5]	0.2 [0.1-0.3]	Highly Toxic	Acute Toxicity I (very toxic to aquatic life)	Acute Cat. I

Legend:

USEPA = United States Environmental Protection Agency

OECD = Organization for Economic Co-operation and Development

GHS = Global Harmonization System

mg/L = milligrams per liter

Note:

*The value of EC₅₀ at 15 min is used for the risk assessment.

Table 3. Ecotoxicity Assessment Scale

LC ₅₀ or EC ₅₀ Concentration Range (mg/L)	Hazard Categories (USEPA 2017)	Hazard Classes (OECD 2001)	Acute Aquatic Toxicity (GHS 2005)
< 0.01	Super Toxic	Acute Toxicity I (very toxic to aquatic life)	Acute Cat. I
0.01 to 0.1	Extremely Toxic		
0.1 to 1	Highly Toxic		
1 to 10	Moderately Toxic	Acute Toxicity II (toxic to aquatic life)	Acute Cat. II
10 to 100	Slightly Toxic	Acute Toxicity III (harmful to aquatic life)	Acute Cat. III
100 to 1000	Practically Nontoxic	—	—
> 1000	Relatively Harmless	—	—

Legend:

OECD = Organization for Economic Co-operation and Development

USEPA = United States Environmental Protection Agency

mg/L = milligrams per liter

7.2 Criteria for Valid Assay

The phenol positive control must meet specified EC₅₀ criteria as stated in section 5.3 for a test to be considered valid.

8 Conclusions

This study reports the aquatic toxicity for the new munitions compounds DNGU, DNP, HK-56, LLM-105 and TNBA via the Microtox Acute Toxicity assay. Results show that DNGU was not considered toxic, with a maximal concentration of 1,000 mg/L., DNP was slightly toxic (EC₅₀: 13.55 mg/L); HK-56 is considered moderately toxic with an EC₅₀ of 1.1 mg/L. LLM-105 and TNBA are highly toxic (0.8 and 0.4 mg/L respectively). LLM-105, HK-56, and TNBA would be considered hazards for aquatic life, while DNP and DNGU are not by OECD hazard class guidelines [6].

9 Recommendations

The acute aquatic toxicity of LLM-105, HK-56, and TNBA are of concern and further testing and evaluation should be continued to determine if environmental releases would pose a threat following use of these test articles. Elevated toxicity may cause difficulties in obtaining a wastewater discharge permit if disposal to natural rivers or streams of any portion of the waste liquors is desired. The limited toxicity of DNGU and DNP is encouraging; however, exposure to DNP can potentially cause skin-sensitizing reactions, so further analysis of exposure scenarios is recommended. The water solubility of both of these compounds may be of concern; however,

Toxicology Study No. S.0002728b-15, April 2018

the lower toxicity may mitigate the issue. LLM-105 and TNBA were also found to potentially act as skin sensitizers based upon additional skin sensitization testing carried out by APHC [9]. This raises additional concerns based on their high toxicity and relatively high water solubility. Further *in vitro* and *in vivo* testing may be warranted for any of these compounds if development is to continue.

10 Point of Contact


Dr. Emily N. Reinke, the Study Director, is the point of contact for this project. She may be reached at DSN 584-3980 or commercial 410-436-3980.

Toxicology Study No. S.0002728b-15, April 2018

Submitted by:

U.S. Army Public Health Center
Health Effects Division
MCHB-PH-HEF
Aberdeen Proving Ground, MD 21010-5403
410-436-3980

Prepared by:




Emily N. Reinke, Ph.D., D.A.B.T.
Biologist
Health Effects Division
U.S. Army Public Health Center (APHC)



Date


Approved by:



Michael J. Quinn Jr., Ph.D.
Division Chief
Health Effects Division
U.S. Army Public Health Center (APHC)



Date



Mark S. Johnson, Ph.D., D.A.B.T.
Directorate Director, Toxicology
U.S. Army Public Health Center (APHC)



Date

Appendix A

References

1. Department of the Army. 2007. *Regulation 200-1. Environmental Protection and Enhancement*. Washington DC.
2. Department of the Army. 2007. *Regulation 40-5. Preventive Medicine*. Washington DC.
3. Department of the Army. 2003. *Regulation 70-1. Army Acquisition Policy* Washington DC.
4. Department of Defense. 1998. *Department of Defense Instruction (DoDi) 4715.4, Pollution Prevention*. <http://www.dtic.mil/whs/directives/corres/pdf/471504p.pdf>.
5. AERTA. 2012. *Requirement PP-3-02-05, "Compliant Ordnance Lifecycle for Readiness of the Transformation and Objective Forces."*
6. OECD. 2001. *Harmonized Integrated Classification System for Human and Environmental Hazards of Chemical Substances and Mixtures*.
7. APHC (Prov). 2016. *Toxicology Study No. S.0024589d-15, Direct Peptide Reactivity Assay of the Novel Energetic, 3,4-Dinitropyrazole (DNP)*. Aberdeen Proving Ground, MD.
8. APHC (Prov). 2016. *Toxicology Study No. S.0024589d-15, Human Cell Line Activation Test of the Novel Energetic 3,4-Dinitropyrazole*. Aberdeen Proving Ground, MD.
9. APHC. 2017. *Toxicology Study No. S.0039820-16, Human Cell Line Activation Test of the Novel Energetics 2,6-pyrazinediamine 3,5-dinitro 1-oxide (LLM-105) and 2,4,6-trinitro-3-bromoanisole (TNBA)*. Aberdeen Proving Ground, MD.
10. Burdette, L.J., L.L. Cook, and R.S. Dyer. 1988. *Convulsant properties of cyclotrimethylenetrinitramine (RDX): spontaneous audiogenic, and amygdaloid kindled seizure activity*. Toxicol Appl Pharmacol **92**(3): 436-44.
11. Kasuske, L., J.M. Schofer, and K. Hasegawa. 2009. *Two marines with generalized seizure activity*. J Emerg Nurs **35**(6): 542-3.
12. Stone, W.J., T.L. Paletta, E.M. Heiman, J.I. Bruce, and J.H. Knepshield. 1969. *Toxic effects following ingestion of C-4 plastic explosive*. Arch Intern Med **124**(6): 726-30.
13. Williams, L.R., V. Aroniadou-Anderjaska, F. Qashu, H. Finne, V. Pidoplichko, D.I. Bannon, and M.F. Braga. 2011. *RDX Binds to the GABAA Receptor-Convulsant Site and Blocks GABAA Receptor-Mediated Currents in the Amygdala: A Mechanism for RDX-Induced Seizures*. Environmental Health Perspectives **119**(3): 357-63.

Toxicology Study No. S.0002728b-15, April 2018

14. Lish, P.M., B.S. Levine, E.M. Marianna-Furedi, J.M. Sagartz, and V.S. Rac. 1984. *Twenty-Four Month Chronic Toxicity/Carcinogenicity Study of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) in the B6C3F1 Hybrid Mouse*, ADA No. 160774.
15. Parker, G.A., G. Reddy, and M.A. Major. 2006. *Reevaluation of a twenty-four-month chronic toxicity/carcinogenicity study of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) in the B6C3F1 hybrid mouse*. Int J Toxicol **25**(5): 373-8.
16. Lima, D.R., M.L. Bezerra, E.B. Neves, and F.R. Moreira. 2011. *Impact of ammunition and military explosives on human health and the environment*. Reviews on Environmental Health **26**(2): 101-10.
17. RAIS. 2012. *Formal Toxicity Summary for 2,4,6-TRINITROTOLUENE*. Risk Assessment Information System.
18. USACHPPM. 2007. *Environmental Health Evaluation for CA 07-00 (IM Fill DEMN) Formulation of New, Environmentally Benign Missile Propellants (To Eliminate TNT-Based Fills)*.
19. APHC. 2016. *Type Protocol Report No. 70-iv16-03-01. The Ames Test for Mutagenicity*. Aberdeen Proving Ground, MD.
20. APHC. 2017. *TOX SOP 068, Xenometrix AMES Test Kit*. Aberdeen Proving Ground, MD.
21. APHC. 2017. *TOX SOP 037, Operation and Maintenance of the Microtox Analyzer*. Aberdeen Proving Ground, MD.
22. APHC. 2017. *Type Protocol Report No. OFMA-92-iv-17-03-01. Microtox Toxicity Testing System*. Aberdeen Proving Ground, MD.
23. Resta, J.J. 2016. *Director's Policy Memorandum No. 70-1, Good Laboratory Practice Policy*. APHC Quality Systems and Regulatory Compliance Office.
24. Code of Federal Regulations (CFR) (1989). *Title 40 CFR Part 792, Good Laboratory Practice Standards*. Code of Federal Regulations. from <http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&SID=03a4fd2c79bd074423f47bc15f186e00&rqn=div5&view=text&node=40:33.0.1.1.3&idno=40>.
25. Dutka, B.J. and K.K. Kwan. 1981. *Comparison of three microbial toxicity screening tests with the Microtox test*. Bull Environ Contam Toxicol **27**(6): 753-7.
26. McFeters, G.A., P.J. Bond, S.B. Olson, and Y.T. Tchan. 1983. *A comparison of microbial bioassays for the detection of aquatic toxicants*. Water Research **17**(12): 1757-1762.
27. Riva, M.C., J. Ribo, G. Gilbert, and P. Alanon. 2007. *Acute toxicity of leather processing effluents on *Vibrio fisheri* and *Brachydanio rerio**. Afinidad. **528**: 182-188.

Toxicology Study No. S.0002728b-15, April 2018

28. USEPA. 2017. *Technical Overview of Ecological Risk Assessment, Analysis phase: Ecological effects characterization, ecotoxicity categories for terrestrial and aquatic organisms*. U.S. Environmental Protection Agency.
29. UNECE. 2015. *The Globally Harmonized System of Classification and Labelling of Chemicals (GHS)*. New York and Geneva.

Appendix B

QUALITY ASSURANCE STATEMENT


For: Toxicology Study No. S.0002728-15, Protocol No. 0FMA-92-iv16-06-01A,B,C,D,E, Microtox Toxicity Testing of the Novel Energetics, 1,4-Dinitroglycoluril (DNGU), 3,4-Dinitropyrazole (DNP), 1,4,7-trinitrohexahydro-1Himidazo[4,5-b]pyrazine-2(3H)-one (HK-56), 2,6-diamino-3,5-dinitro-2,3-dihydropyrazine 1-oxide (LLM-105), and 2,4,6-trinitro-3-bromoanisole (TNBA), the following Good Laboratory Practice Standard Inspections were conducted:

Study Specific Critical Phase Inspected/Audited	Date Inspected /Audited	Date Reported to Management/SD
Type Protocol Good Laboratory Practice Standard Review	06/29/2016	06/29/2016
Test Article Specific Type Protocol Modifications Review	02/13/2017	02/13/2017
Analytical Chemistry Support – QA review of Dosing Solution Concentration Verification	12/06/2016	12/06/2016
Microtox - Reagent and Test System Storage and Labeling requirements	05/02/2017	05/05/2017
Microtox - Data Processing and Raw Data Documentation Procedures	05/02/2017	05/05/2017
Microtox - Compliance with GLP requirements for Test Facility SOPs	05/02/2017	05/05/2017
Microtox - Calibration Verification of Equipment - Balance and Pipettes	05/02/2017	05/05/2017
Microtox Test Study Endpoint Criteria Compliance	05/02/2017	05/02/2017
Study Raw Data Good Laboratory Practice Standard Review	01/10/2018	01/10/2018
Final Study Good Laboratory Practice Standard Report Review	01/10/2018	01/10/2018

Note 1: All findings were made known to the Study Director and the Program Manager at the time of the audit/inspection. If there were no findings during the inspection, the inspection was reported to Management and the Study Director on the date shown in the table.

Note 2: This report has been audited by the Quality Assurance Unit (QSARC), and is considered to be an accurate account of the data generated and of the procedures followed

Note 3: In addition to the study specific critical phase inspections listed here, general facility and process based inspection not specifically related to this study are done monthly or annually in accordance with QA Standard Operating Procedure.


 Michael P. Kefauver
 Good Laboratory Practice Standard
 Quality Assurance Specialist, QSARC


 Date

Appendix C

Archives and Study Personnel

C-1 Archives

All raw data, documentation, records, protocols, contributing scientist reports, and a copy of the final report generated as a result of this study will be archived in the storage facilities of the Toxicology Portfolio, APHC, for a minimum of five (5) years following submission of the final report to the Sponsor. If the report is used to support a regulatory action, it shall, along with all supporting data, be retained indefinitely.

Records on the test system will be archived by the Toxicology Portfolio for a minimum of five (5) years following submission of the final report to the Sponsor. If the report is used to support a regulatory action, it shall, along with all supporting data, be retained indefinitely.

The present study used the Toxicology Study No. S.0002728b-15, Protocol No. 0FMA-92-iv16-06-01A,B,C,D,E,

The protocol, raw data, summary data, and the final report pertaining to this study will be physically maintained within Building E-2100, APHC. These data may be scanned to a computer disk. Scanned study files will be stored electronically with the study data in the archive.

Archived SOPs can be found in the Master Control database at APHC. Maintenance and calibration logbooks may be found in Room 1026, Building E-2100, APHC, APG, MD 21010.

Archivist: Martha Thompson

C-2 Personnel

Management: Mark Johnson, Ph.D., D.A.B.T., Portfolio Toxicology Director; Michael J. Quinn, Ph.D., Program Manager, Health Effects Research Program (HERP).

Study Director: Emily N. Reinke, Ph.D., Biologist, HERP.

Technical staff: Alyssa Sikorski, M.S., ORISE Fellow.

Quality Assurance: Michael P. Kefauver, Chemist, Quality Systems and Regulatory Compliance Office. .

Appendix D
Microtox Test Reagents

Table D-1. Microtox Test Reagents

Microtox Reagents	Source	Lot #	Date Expiration
Modern Water Microtox Diluent	Modern Water	14K4141	10/2017
Modern Water Microtox Acute Reagent	Modern Water	15K4119A	10/2017
Modern Water Microtox Acute Reagent	Modern Water	16M4144	12/2018
Dimethyl sulfoxide	Sigma	RNB7475	11/2018
Dimethyl sulfoxide	Sigma	RNBF2710	2/2018
Dimethyl sulfoxide	Sigma	RNBF4251	5/2018
Phenol	Sigma-Aldrich	SHBF1351V	
Modern Water Microtox Reconstitution Solution	Modern Water	16D4031	4/2019

Appendix E


DNGU Microtox Test Data Tables and Calculations

Nominal Concentration (mg/mL; 100x test concentration)	Corrected Working Concentration (mg/mL; 100x test concentration)		
	Test 1	Test 2	Test 3
0.781	0.834*	0.870*	0.852*
1.563	1.668	1.740	1.704
3.125	3.336	3.480	3.408
6.250	6.672	6.960	6.818
12.50	13.344	13.920	13.623
25.00	26.688	27.840	27.264
50.00	53.376	55.680	54.528
100.00	106.752	111.360	109.056

Note:

*Working concentration measured by MDV, final corrected concentrations were calculated from lowest measured working concentration.

DNGU EC50 (mg/L; 95% CI)		
5 minute	15 minute	30 minute
492.3 (451.0 to 537.4)	273.3 (251.7 to 297.6)	173.9 (158.1 to 191.4)



Appendix F

DNP Microtox Test Data Tables and Calculations


Nominal Concentration (mg/mL; 100x test concentration)	Corrected Working Concentration (mg/mL; 100x test concentration)		
	Test 1	Test 2	Test 3
3.906	3.44*	2.22*	4.00*
7.812	6.88	4.44	8.00
15.624	13.76	8.88	16.00
31.248	27.52	17.76	32.00
62.496	55.04	35.52	64.00
124.992	110.08	71.04	128.00
249.984	220.16	142.08	256.00
499.968	440.32	284.16	512.00

Note:

*Working concentration measured by MDV, final corrected concentrations were calculated from lowest measured working concentration.

DNP EC50 (mg/L; 95% CI)		
5 minute	15 minute	30 minute
13.62 (12.58 to 14.75)	10.92 (10.15 to 11.75)	9.129 (8.296 to 10.05)

Microtox Toxicity of DNP



Appendix G

HK-56 Microtox Test Data Tables and Calculations


Nominal Concentration (mg/mL; 100x test concentration)	Corrected Working Concentration (mg/mL; 100x test concentration)		
	Test 1	Test 2	Test 3
0.39	0.35*	0.39*	0.36*
0.78	0.70	0.78	0.72
1.56	1.40	1.56	1.44
3.12	2.80	3.12	2.88
6.24	5.60	6.24	5.76
12.48	11.20	12.48	11.52
24.96	22.40	24.96	23.04
49.92	44.80	49.92	46.08

Note:

*Working concentration measured by MDV, final corrected concentrations were calculated from lowest measured working concentration.

HK-56 EC50 (mg/L; 95% CI)		
5 minute	15 minute	30 minute
2.584 (2.215 to 3.014)	1.082 (0.9474 to 1.236)	0.6204 (0.5196 to 0.7407)

Microtox Toxicity of HK-56



Appendix H

LLM-105 Microtox Test Data Tables and Calculations


Nominal Concentration (mg/mL; 100x test concentration)	Corrected Working Concentration (mg/mL; 100x test concentration)			
	Test 1	Test 2	Test 3	Test 4
0.977	0.49*	0.18*	0.61*	0.96
1.954	0.98	0.36	1.22	1.92
3.908	1.96	0.72	2.44	3.84
7.816	3.92	1.44	4.88	7.68
15.632	7.84	2.88	9.76	15.36
31.264	15.68	5.76	19.52	30.72
62.528	31.36	11.52	39.04	61.44
125.056	62.72	23.04	78.08	122.88

Note:

*Working concentration measured by MDV, final corrected concentrations were calculated from lowest measured working concentration.

LLM-105 EC50 (mg/L; 95% CI)		
5 minute	15 minute	30 minute
1.120 (1.036 to 1.210)	0.7736 (0.6863 to 0.8720)	0.6919 (0.5957 to 0.8037)

Microtox Toxicity of LLM-105



Appendix I

TNBA Microtox Test Data Tables and Calculations

Nominal Concentration (mg/mL; 100x test concentration)	Corrected Working Concentration (mg/mL; 100x test concentration)		
	Test 1	Test 2	Test 3
0.39	0.21*	0.27*	0.27*
0.78	0.42	0.54	0.54
1.56	0.84	1.08	1.08
3.12	1.68	2.16	2.16
6.24	3.36	4.32	4.32
12.48	6.72	8.64	8.64
24.96	13.44	17.28	17.28
49.92	26.88	34.56	34.56

Note:

*Working concentration measured by MDV, final corrected concentrations were calculated from lowest measured working concentration.

TNBA EC50 (mg/L; 95% CI)		
5 minute	15 minute	30 minute
0.7819 (0.4483 to 1.364)	0.3621 (0.2870 to 0.4569)	0.1347 (0.1484 to 0.2505)

Microtox Toxicity of TNBA

